Molecular Oncology
Volume 3, Issue 3 , Pages 248-261 , June 2009

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

  • Tim P. Green

      Affiliations

    • Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • Corresponding Author InformationCorresponding author. c/o Paul Elvin, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK. Tel.: +44 1625 516 178; fax: +44 1625 510 097.
    • ,
  • Mike Fennell

      Affiliations

    • Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Robin Whittaker

      Affiliations

    • Clinical Development, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Jon Curwen

      Affiliations

    • Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Vivien Jacobs

      Affiliations

    • Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Jack Allen

      Affiliations

    • Clinical Pharmacology and DMPK, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Armelle Logie

      Affiliations

    • Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Judith Hargreaves

      Affiliations

    • Clinical Pharmacology and DMPK, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • D. Mark Hickinson

      Affiliations

    • Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Robert W. Wilkinson

      Affiliations

    • Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Paul Elvin

      Affiliations

    • Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Brigitte Boyer

      Affiliations

    • Inserm U784, 46 Rue d'Ulm, 75230 Paris, Cedex 05, France
    • ,
  • Neil Carragher

      Affiliations

    • Advanced Science and Technology Laboratory, AstraZeneca R&D, Charnwood, Bakewell Road, Loughborough, LE11 5RH, UK
    • ,
  • Patrick A. Plé

      Affiliations

    • Discovery Enabling Capabilities & Sciences, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Alun Bermingham

      Affiliations

    • Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • Present address: Molecular Targets Development Program, National Cancer Institute, Building 562, Fort Detrick, Frederick, MD 21702-1201, USA.
    • ,
  • Geoffrey A. Holdgate

      Affiliations

    • Discovery Enabling Capabilities & Sciences, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Walter H.J. Ward

      Affiliations

    • Discovery Enabling Capabilities & Sciences, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Laurent F. Hennequin

      Affiliations

    • Cancer and Infection Research Area Reims, AstraZeneca, Centre de Recherches, Z.I. La Pompelle B.P. 1050, 51689 Reims Cedex 2, France
    • ,
  • Barry R. Davies

      Affiliations

    • Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
    • ,
  • Gerard F. Costello

      Affiliations

    • Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK

Received 7 November 2008 ,Revised 19 January 2009 ,Accepted 20 January 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1574-7891(09)00018-0

doi: 10.1016/j.molonc.2009.01.002

Molecular Oncology
Volume 3, Issue 3 , Pages 248-261 , June 2009

Article Tools

* Image Usage & Resolution